3Z is a Reykjavik based drug discovery company that specializes in developing novel therapeutics for ADHD and insomnia. They have recently closed a $2 million funding round, led by experienced investors in the pharmaceutical and medical technology industry. This funding will help accelerate the completion of preclinical studies on 3Z's lead therapeutic candidates.

What sets 3Z apart is their unique zebrafish screening platform, which allows for cost-effective high-volume screens in vivo. Using this platform, they have identified both novel and repurposed therapeutics for ADHD and insomnia. Their lead therapeutics are currently being re-assayed in mammalian models to validate their potential.

Amidst a market filled with stimulants, 3Z's novel ADHD therapeutics stand out as non-stimulants with fewer side-effects. They aim to provide an alternative for non-responders, addressing a gap in the market. Additionally, their insomnia therapeutic offers a novel mechanism of action that may combat both insomnia and metabolic syndrome, two indications with significant comorbidity.

Led by CEO Karl Karlsson, a respected expert in behavioral neuroscience and professor in Biomedical Engineering, 3Z is well-positioned to bring these innovative therapies to the market. With the successful funding round, 3Z can now focus on finalizing their assets for clinical trials and managing outsourcing activities. To learn more about 3Z, visit their website at www.

3z. is or follow them on Linkedin